Accelerating Cell Therapy Translation from Lab to Bedside
Live Webinar: October 12, 2026, 9 am ET, 6 am PT
Cell therapies have the potential to transform outcomes across multiple diseases, but the path from promising preclinical results to a viable clinical-stage therapy is rarely straightforward. Researchers developing these treatments face multiple scientific, technical, and regulatory hurdles when translating early-stage discoveries into treatments that can reach patients.
In this webinar, brought to you by ACROBiosystems, researchers at the forefront of cell therapy development will share their firsthand insights into the path from bench to bedside, including scale-up, analytical development, and navigating regulatory requirements.
Natalie Francis from King’s College London will discuss the development of a pluripotent stem cell therapy designed to treat retinal degeneration through a gene-agnostic approach, offering hope for patients who have already experienced significant vision loss.
Dominik Schmiedel from the Fraunhofer Institute for Cell Therapy and Immunology (IZI) will present a platform for engineering natural killer (NK) cells to express defined TCR-CD3 complexes, enabling an off-the-shelf approach to targeting intracellular antigens in infectious disease and cancer.
Topics to be covered in this webinar
- Key scientific and manufacturing hurdles in advancing cell therapies from early research to clinical-stage development
- Developing a gene-agnostic pluripotent stem cell therapy for retinal degeneration
- Engineering TCR-NK cells as a scalable, off-the-shelf platform for targeting intracellular antigens in infectious disease and cancer
FILL THE FORM BELOW
© An Imprint of coreinteltech | All rights reserved | Privacy Policy